$292.76
0.70% yesterday
Nasdaq, May 20, 10:00 pm CET
ISIN
US5588681057
Symbol
MDGL
Sector
Industry

Madrigal Pharmaceuticals, Inc. Stock price

$292.76
-2.26 0.77% 1M
-24.33 7.67% 6M
-15.81 5.12% YTD
+60.66 26.14% 1Y
+226.05 338.85% 3Y
+170.65 139.75% 5Y
+212.26 263.68% 10Y
Nasdaq, Closing price Tue, May 20 2025
+2.04 0.70%
ISIN
US5588681057
Symbol
MDGL
Sector
Industry

Key metrics

Market capitalization $6.50b
Enterprise Value $5.77b
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF negative
EV/Sales (TTM) EV/Sales 18.19
P/S ratio (TTM) P/S ratio 20.48
P/B ratio (TTM) P/B ratio 9.14
Revenue (TTM) Revenue $317.38m
EBIT (operating result TTM) EBIT $-425.15m
Free Cash Flow (TTM) Free Cash Flow $-396.41m
Cash position $848.07m
EPS (TTM) EPS $-18.04
P/E forward negative
P/S forward 9.72
EV/Sales forward 8.63
Short interest 21.43%
Show more

Is Madrigal Pharmaceuticals, Inc. a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,789 stocks worldwide.

Madrigal Pharmaceuticals, Inc. Stock Analysis

Unlock Scores for Free

Analyst Opinions

17 Analysts have issued a Madrigal Pharmaceuticals, Inc. forecast:

15x Buy
88%
1x Hold
6%
1x Sell
6%

Analyst Opinions

17 Analysts have issued a Madrigal Pharmaceuticals, Inc. forecast:

Buy
88%
Hold
6%
Sell
6%

Financial data from Madrigal Pharmaceuticals, Inc.

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Mar '25
+/-
%
317 317
-
100%
- Direct Costs 12 12
2,014% 2,014%
4%
305 305
53,667% 53,667%
96%
- Selling and Administrative Expenses 521 521
202% 202%
164%
- Research and Development Expense 208 208
26% 26%
66%
-424 -424
7% 7%
-134%
- Depreciation and Amortization 1.31 1.31
130% 130%
0%
EBIT (Operating Income) EBIT -425 -425
6% 6%
-134%
Net Profit -392 -392
12% 12%
-123%

In millions USD.

Don't miss a Thing! We will send you all news about Madrigal Pharmaceuticals, Inc. directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Madrigal Pharmaceuticals, Inc. Stock News

Positive
Seeking Alpha
4 days ago
Madrigal Pharmaceuticals' Rezdiffra for NASH achieved $137.3M in Q1 '25 sales, surpassing analyst estimates and indicating strong growth, but the stock hasn't rallied. Near-term catalysts include potential approval of Rezdiffra in Europe, Q2 '25 earnings and business development, with MDGL indicating they are keen to add to their pipeline. Results from the MAESTRO-NASH OUTCOMES trial are not ex...
Positive
The Motley Fool
8 days ago
Investing in promising companies before their stock prices soar is an excellent recipe for earning life-changing returns. However, with hundreds of companies vying for investors' attention, separating the wheat from the chaff can be challenging.
Neutral
GlobeNewsWire
11 days ago
CONSHOHOCKEN, Pa., May 10, 2025 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL), a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), today announced positive two-year results from the open-label compensated MASH cirrhosis (F4c) arm of the Phase 3 MAESTRO-NAFLD-1 trial of Rezdiffra. Patients (n=122) i...
More Madrigal Pharmaceuticals, Inc. News

Company Profile

Madrigal Pharmaceuticals, Inc. engages on the development and commercialization of innovative therapeutic candidates for the treatment of cardiovascular, metabolic, and liver diseases. Its lead product, MGL-3196, is used for the treatment of non-alcoholic steatohepatitis and familial hypercholesterolemia. The company was founded by Rebecca Taub and Edward Chiang on September 2011 and is headquartered in Fort Washington, PA.

Head office United States
CEO William Sibold
Employees 528
Founded 2011
Website www.madrigalpharma.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today